Company: Odylia Therapeutics
Job title: Chief Scientific Officer
Ashley Winslow is Chief Scientific Officer at Odylia Therapeutics, a nonprofit biotech focused on developing gene therapies for rare retinal disorders. Odylia develops gene therapies in collaboration with rare disease patient groups and a strategic network of CRO and academic partners, with the aim to de-risk products for investment and late stage development by commercial partners.
Ashley received her PhD in Medical Genetics from the University of Cambridge and completed her postdoctoral work at Massachusetts General Hospital and Harvard Medical School. Before joining Odylia, Ashley worked in the Precision Medicine and Human Genetics and Computational Biomedicine group at Pfizer and the Orphan Disease Center at the University of Pennsylvania. She has experience overseeing drug development from target discovery to early phase clinical programs.
PANEL DISCUSSION: Evaluating the Current Commercial Landscape in Light of a Recent Ophthalmic Approval 12:30 pm
Exciting work is being done to develop gene therapies to treat a variety of ophthalmic disorders, and there is already a retinal gene therapy on the market. This leads to key questions surrounding reimbursement, access to therapies, and effective commercialization and product differentiation of gene therapies to come. This panel discussion will address various topics…Read more
day: Day Two
Exploring Innovative Partnerships to Enable Gene Therapy Manufacturing for Rare Ocular Disorders 2:00 pm
• Investigating current manufacturing challenges and leveraging unique opportunities in gene therapy development for rare ocular disorders • Developing innovative partnerships with academia and industry to decrease costs, de-risk gene therapies, and overcome obstacles in developmentRead more
day: Day Two